newsfilter
← Latest News
GlobeNewswire·

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

  • Capricor Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its resubmitted Biologics License Application for Deramiocel.
  • The CRL states the FDA does not consider the data sufficient to establish substantial evidence of effectiveness and cites clinical deficiencies.
  • CEO Linda Marbán expressed disappointment but affirmed the company stands behind the rigor of its data from the HOPE-2 & HOPE-3 trials which met primary endpoints.
  • Capricor announced a conference call & webcast scheduled for Monday, November 23, at 8:30 a.m. ET to discuss the CRL.
  • As of September 30, 2026, the company held approximately $198.5 million in cash & equivalents, sufficient to fund operations for at least 12 months.
  • The company is reviewing operating costs to extend its cash runway following the regulatory setback.
  • Deramiocel is an allogeneic cardiosphere-derived cell therapy currently in development for Duchenne muscular dystrophy (DMD).
  • Deramiocel holds Orphan Drug, RMAT, & Rare Pediatric Disease designations in the U.S. for the treatment of DMD.
  • DMD is a severe genetic disorder affecting approximately 15,000 individuals in the U.S., primarily males, with no current cure.
  • Capricor is also advancing its StealthX™ exosome platform for targeted delivery of therapeutics across various diseases.
Company
Capricor Therapeutics
Keywords
Nasdaq:CAPR, Capricor Therapeutics